Chimeric Therapeutics (ASX:CHM) Interest Paid : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Interest Paid?

Chimeric Therapeutics's Interest Paid for the six months ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics's Interest Paid for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics Interest Paid Historical Data

The historical data trend for Chimeric Therapeutics's Interest Paid can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Interest Paid Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Interest Paid

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Paid	Get a 7-Day Free Trial			-	-	-	-	-

Chimeric Therapeutics Interest Paid Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Paid represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Interest Paid for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Chimeric Therapeutics Interest Paid Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Interest Paid provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Interest Paid

Comparable Companies

Traded in Other Exchanges

N/A

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

No Headlines